Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Bioqube Ventures
BioCentury | Oct 15, 2024
Emerging Company Profile
Commit: Activating the complement pathway to deeply deplete target cells
Launched in May, Danish company’s tech engages C1q to trigger complement-induced killing of cancer or autoimmune cells
BioCentury | Jul 18, 2024
Finance
Venture Report: Five biotechs raise nearly $800M in two-day flurry
Plus: New capital for CytoReason, Truvian and Renalys
BioCentury | May 9, 2024
Finance
Venture report: Big rounds for Bluejay, Attovia and Zenas
Strong fundraising week also included launches by Prologue and Commit, plus raises by Aardvark, Memo and OverT
BioCentury | Apr 26, 2024
Finance
Venture report: Arch, Foresite $1B AI play Xaira starting with Baker lab’s de novo biologics
Plus rounds for Rubedo, Flindr, Endeavor, SynOx and more
BioCentury | Mar 6, 2023
Finance
As clinical evidence mounts for bispecific, VCs back Bicara with $108M series B
Red Tree branches beyond West Coast sweet spot to co-lead with RA Capital in backing Biocon spinout
BioCentury | Sep 16, 2022
Finance
Sept. 15 Quick Takes: Khosla seeds Cas13 company Carver
Plus RGImmune launches with F-Prime’s backing and updates from Pfizer, Tridek-One
BioCentury | Oct 23, 2021
Product Development
Oct. 22 Quick Takes: FDA approves Genentech’s ocular implant for wet AMD
$118M IPO values Xilio at $427M, plus Genentech, Merck, Sanofi and more
BioCentury | Feb 19, 2021
Emerging Company Profile
Primmune: tolerable TLR7 agonists for systemic immune responses
Emerging Company Profile: San Diego-based Primmune is developing oral host-directed antivirals that activate TLR7 signaling
BioCentury | Jan 13, 2021
Deals
Jan. 12 Quick Takes: $230M series B for Flagship’s ‘gene writer’ Tessera; plus Elucida, Vedanta, AbbVie-Dragonfly, Primmune
Flagship Pioneering Gene Writing company Tessera Therapeutics Inc. raised a $230 million series B round co-led by Alaska Permanent Fund Corporation, Altitude Life Science Ventures and SoftBank Vision
BioCentury | Jun 10, 2020
Finance
Belgium’s Bioqube earmarking some of planned €100M fund for ‘de-risking’ projects
With first €60M close, Bioqube seeks mix of traditional early-stage deals and asset-centric investments
Items per page:
1 - 10 of 12